Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration.

[1]  P. Narciso,et al.  The therapeutic phase I trial of the recombinant native HIV-1 Tat protein , 2008, AIDS.

[2]  A. Caputo,et al.  Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. , 2008, Current drug delivery.

[3]  R. Gavioli,et al.  Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. , 2008, Vaccine.

[4]  R. Gavioli,et al.  The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. , 2008, Vaccine.

[5]  T. Delair,et al.  Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. , 2007, Vaccine.

[6]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[7]  M. Magnani,et al.  Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. , 2007, Vaccine.

[8]  G. Altavilla,et al.  Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes , 2007, Pharmaceutical Research.

[9]  M. Robert-Guroff,et al.  Problems and emerging approaches in HIV/AIDS vaccine development , 2007, Expert opinion on emerging drugs.

[10]  M. Magnani,et al.  Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. , 2006, AIDS.

[11]  M. Houghton,et al.  Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. , 2006, The Journal of general virology.

[12]  L. Kwak,et al.  Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Giuseppe Altavilla,et al.  DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. , 2006, Vaccine.

[14]  Y. Perrie,et al.  Particulate delivery systems for vaccines: what can we expect? , 2006, The Journal of pharmacy and pharmacology.

[15]  Roger Le Grand,et al.  Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[16]  R. Mumper,et al.  HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. , 2006, Vaccine.

[17]  S. Davis.  The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. , 2006, Vaccine.

[18]  B. Ensoli,et al.  Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. , 2006, Vaccine.

[19]  Manmohan J. Singh,et al.  A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. , 2006, Vaccine.

[20]  S. Kasturi,et al.  Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. , 2005, Biomaterials.

[21]  I. Sjöholm,et al.  Starch microparticles as vaccine adjuvant , 2005, Expert opinion on drug delivery.

[22]  L. Barbu-Tudoran,et al.  Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[23]  B. Frisch,et al.  Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. , 2005, Molecular immunology.

[24]  Hans P Merkle,et al.  Formulation aspects of biodegradable polymeric microspheres for antigen delivery. , 2005, Advanced drug delivery reviews.

[25]  M. Marchisio,et al.  Core–shell microspheres by dispersion polymerization as promising delivery systems for proteins , 2005, Journal of biomaterials science. Polymer edition.

[26]  M. Houghton,et al.  Cationic microparticles are a potent delivery system for a HCV DNA vaccine. , 2004, Vaccine.

[27]  Manmohan J. Singh,et al.  Adsorption of a Novel Recombinant Glycoprotein from HIV (Env gp120dV2 SF162) to Anionic PLG Microparticles Retains the Structural Integrity of the Protein, Whereas Encapsulation in PLG Microparticles Does Not , 2004, Pharmaceutical Research.

[28]  B. Ensoli,et al.  Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. , 2004, Current opinion in biotechnology.

[29]  R. Gavioli,et al.  Recent advances in the development of HIV-1 Tat-based vaccines. , 2004, Current HIV research.

[30]  J. Heeney,et al.  Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. , 2004, Vaccine.

[31]  G. Altavilla,et al.  Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. , 2004, Vaccine.

[32]  Russell J Mumper,et al.  Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. , 2004, Vaccine.

[33]  D. Sesardic,et al.  European union regulatory developments for new vaccine adjuvants and delivery systems. , 2004, Vaccine.

[34]  Jayanth Panyam,et al.  Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[35]  M. Marinaro,et al.  Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. , 2003, Vaccine.

[36]  A. Scoglio,et al.  Efficient mucosal delivery of the HIV‐1 Tat protein using the synthetic lipopeptide MALP‐2 as adjuvant , 2003, European journal of immunology.

[37]  Manmohan J. Singh,et al.  Microparticles as vaccine adjuvants and delivery systems , 2003, Expert review of vaccines.

[38]  Giuseppe Del Giudice,et al.  MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile , 2003, Expert review of vaccines.

[39]  G. Altavilla,et al.  Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. , 2003, Vaccine.

[40]  Thomas Kissel,et al.  In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. , 2003, Biomaterials.

[41]  S. Moretti,et al.  Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses1 , 2002, The Journal of Immunology.

[42]  J. Ulmer,et al.  Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines , 2001, Journal of Virology.

[43]  G. Ott,et al.  Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[44]  Manmohan J. Singh,et al.  Cationic microparticles: A potent delivery system for DNA vaccines. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Manmohan J. Singh,et al.  Advances in vaccine adjuvants , 1999, Nature Biotechnology.

[46]  A. Coombes,et al.  Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. , 1999, Vaccine.

[47]  J. Heeney,et al.  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine , 1999, Nature Medicine.

[48]  C. Rossi,et al.  DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. , 1999, Journal of immunology.

[49]  H. Sah.  Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[50]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[51]  Langer,et al.  New advances in microsphere-based single-dose vaccines. , 1997, Advanced drug delivery reviews.

[52]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[53]  廷冕 李,et al.  応用 (Application) について , 1981 .

[54]  Manmohan J. Singh,et al.  Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. , 2006, Current drug delivery.

[55]  P van Hoogevest,et al.  MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. , 1995, Pharmaceutical biotechnology.